SS-31 (Elamipretide) – Comprehensive Research Overview (2026)
SS-31, also known as Elamipretide (brand name Forzinity), is a synthetic aromatic-cationic tetrapeptide designed to selectively target mitochondria. It is the first mitochondria-targeted peptide to receive FDA accelerated approval (September 2025) for Barth syndrome. SS-31 binds to cardiolipin in the inner mitochondrial membrane, optimizing electron transport chain function, reducing oxidative stress, and improving cellular energy production. It is researched for mitochondrial diseases, heart failure, kidney disease, and age-related decline.
Chemical Structure and Properties
- Amino Acid Sequence: D-Arg-2',6'-dimethyl-L-Tyr-Lys-Phe-NH₂ (D-Arg-Dmt-Lys-Phe-NH₂)
- Molecular Weight: ≈639.8 Da
- Form: Lyophilized powder or solution for subcutaneous injection
- Key Feature: Highly cell-permeable with ~5,000-fold accumulation in mitochondria via cardiolipin binding
Mechanism of Action
SS-31 selectively binds cardiolipin on the inner mitochondrial membrane, stabilizing it and optimizing electron transport chain supercomplexes. This leads to:
- Improved ATP production and mitochondrial efficiency
- Reduced reactive oxygen species (ROS) leakage and cardiolipin peroxidation
- Inhibition of mitochondrial permeability transition pore opening
- Restoration of mitochondrial cristae structure and morphology
It primarily affects stressed or damaged mitochondria while sparing healthy ones.
Clinical Evidence and Research Findings
SS-31 received FDA accelerated approval for Barth syndrome based on the TAZPOWER trial and long-term extensions showing improvements in muscle strength and function. Phase 2 trials in primary mitochondrial myopathy showed mixed results on exercise performance, while signals exist in heart failure, kidney disease, and ophthalmic indications. It has a growing body of evidence in mitochondrial dysfunction but requires further Phase 3 data for broader approvals.
Benefits (Research & Clinical Observations)
- Improved mitochondrial energy production and muscle function
- Reduction in oxidative stress and inflammation
- Potential benefits in Barth syndrome, heart failure, and kidney disease
- Support for exercise capacity and cellular resilience
- Tissue-protective effects in ischemia-reperfusion models
Typical Dosing Protocols (Approved & Off-Label)
- Approved dosing (Barth syndrome): Weight-based subcutaneous injection (as Forzinity)
- Research protocols: 5–40 mg per day subcutaneously (common range 10–40 mg)
- Cycles: Often 4–12+ weeks with medical supervision
- Administered subcutaneously; titration is common
Safety Profile and Side Effects
SS-31 has demonstrated a favorable safety profile in clinical trials.
Common side effects:
- Mild injection-site reactions
- Generally well-tolerated with no major organ toxicity reported at therapeutic doses
Monitoring recommended: Standard labs for individuals with mitochondrial or cardiac conditions. Long-term safety data continue to accrue post-approval. Contraindicated in known hypersensitivity.
SS-31 vs Other Mitochondrial Peptides – Quick Comparison
| Aspect | SS-31 (Elamipretide) | MOTS-c | BAM15 |
|---|---|---|---|
| Primary Target | Cardiolipin / mitochondria | Metabolic reprogramming | Mitochondrial uncoupling |
| Energy Expenditure | Strong (targeted) | Moderate | Strong |
| Exercise Mimetic | Partial | Yes | Strong |
| Human Clinical Data | Approved (Barth syndrome) | Limited | None |
| FDA Status | Accelerated approval | Not approved | Not approved |
FAQ – Frequently Asked Questions
Is SS-31 FDA approved? Yes. It received FDA accelerated approval in September 2025 for Barth syndrome (as Forzinity).
How does SS-31 work differently from other peptides? It selectively targets cardiolipin in mitochondria to improve energy production and reduce oxidative damage without affecting healthy cells.
Can SS-31 be used with other compounds? Yes. It is often researched alongside other mitochondrial or regenerative peptides, but this should only be done under medical supervision.
How long until results are seen? Improvements in muscle function and energy in Barth syndrome trials were observed within weeks to months of consistent use.
Is SS-31 safe for long-term use? Short- to medium-term data are reassuring; long-term safety is being monitored post-approval.
Summary
SS-31 (Elamipretide) is a groundbreaking mitochondria-targeted tetrapeptide that optimizes cardiolipin function, improves ATP production, and reduces oxidative stress. It holds FDA accelerated approval for Barth syndrome and shows promise in other mitochondrial and metabolic conditions. While clinical data are strongest in rare diseases, broader applications are under active investigation. As with all compounds in this library, SS-31 should only be used under qualified medical supervision with appropriate monitoring.
Disclaimer This overview is strictly educational and based on publicly available scientific literature and regulatory information as of April 2026. It does not constitute medical advice, endorsement, or encouragement of use. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.